hVEGFA/hPD-1/hPD-L1

Nomenclature

C57BL/6JSmo-Vegfatm1(hVEGFA)Pdcd1tm1(hPDCD1)Cd274tm1(hPD-L1)Smoc

Cat. NO.

NM-XA-242143

Strain State

Repository Live

Export PDF

Model Description

The hPD-1/hPD-L1(NM-HU-00100) was crossed with hVEGFA(NM-HU-2000028) to generate hVEGFA/hPD-1/hPD-L1 mice.

Validation Data

image.png

Fig.1 Body weight were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (n=8). (A）Body weight. (B) Body weight change.

image.png

Fig.2 Tumor volume were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice. (A) Tumor volume. (B) Relative tumor volume.

MC38-hVEGFA (1×106) were inoculated subcutaneously into hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (male, 8-week-old, n=8). 

image.png

Fig.3 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Detection of human VEGFA expression in MC38-hVEGFA/hPD-L1 tumor by ELISA (n=2). 

image.png

Fig.4 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Detection of human PD-L1 expression in MC38-hVEGFA/hPD-L1 tumor by FACS (n=2).

image.png

Fig.5 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Body weight were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (female, 13-week-old, n=8). (A）Body weight. (B) Body weight change.

image.png

Fig.6 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Tumor volume were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice. MC38-hVEGFA/hPD-L1 (1×106) were inoculated subcutaneously into hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (female, 13-week-old, n=8). (A) Tumor volume. (B) Relative tumor volume.

image.png

Fig.7 In vivo efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Flow cytometry analysis of tumor-infiltrating lymphocytes (TILs) from MC38-hVEGFA/hPD-L1 tumor by FACS. Tumor-infiltrating lymphocytes (TILs) were collected to carry out an immunophenotypic analysis by flow cytometry (n=4). According to flow cytometric analysis, post-treatment led to a significant increase in the proportion of T cells, and a substantial reduction in the proportion of myeloid cells.


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more

Milestones

Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.

Learn more